Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck

New England Journal of Medicine

Volumn 323, Issue 12, 1990, Pages 795-801

  Hong, Waun ki ^a   Lippman, Scott M ^a   Itri, Loretta M ^c   Karp, Daniel D ^b   Lee, Jin S ^a   Byers, Robert M ^a   Schantz, Stimson P ^a   Kramer, Alan M ^a   Lotan, Reuben ^a   Peters, Lester J ^a   Dimery, Isaiah W ^a   Brown, Barry W ^a   Goepfert, Helmuth ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c Department of Clinical Development ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN;

ADULT; AGED; ARTICLE; CANCER RECURRENCE; CHEILITIS; CONJUNCTIVITIS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRY SKIN; FEMALE; HEAD AND NECK CANCER; HUMAN; HYPERTRIGLYCERIDEMIA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RADIOLOGY; SECOND CANCER; SQUAMOUS CELL CARCINOMA;

EID: 0025091456     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199009203231205     Document Type: Article

References (50)

1. Silverberg E. Boring CC, Squires TS. Cancer statistics, 1990. CA 1990; 40: 9–26.
2. Hong WK, Bromer R. Chemotherapy in head and neck cancer. N Engl J Med 1983; 308: 75–9.
3. Goepfert H. Are we making any progress? Arch Otolaryngol 1984; 110: 562–3.
4. Choksi AJ, Dimery IW, Hong WK. Adjuvant chemotherapy of head and neck cancer: the past, the present, and the future. Semin Oncol 1988; 15: Suppl 3: 45–59.
5. Hong WK, Bromer RH, Amato DA, et al. Patterns of relapse in locally advanced head and neck cancer patients who achieved complete remission after combined modality therapy. Cancer 1985; 56: 1242–5.
6. Lippman SM, Hong WK. Second malignant tumors in head and neck squamous cell carcinoma: the overshadowing threat for patients with early-stage disease. Int J Radial Oncol Biol Phys 1989; 17: 691–4.
7. Slaughter DP, Southwick HW, Smejkal W. “Field cancerization” in oral stratified squamous epithelium: clinical implications of multicentric origin. Cancer 1953; 6: 963–8.
8. Strong MS, Incze J, Vaughan CW. Field cancerization in the aerodigestive tract — its etiology, manifestation, and significance. J Otolaryngol 1984; 13: 1–6.
9. Coltman CA Jr, Dahlberg S. Treatment-related leukemia. N Engl J Med 1990; 322: 52–3.
10. Parker RG, Enstrom JE. Second primary cancers of the head and neck following treatment of initial primary head and neck cancers. Int J Radiat Oncol Biol Phys 1988; 14: 561–4.
11. Lippman SM, Kessler JF Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987; 71: 391–405, 493–515.
12. Lotan R. Effects of vitamin A and its analogs (retinoids) on normal and neoplastic cells. Biochem Biophys Acta 1980; 605: 33–91.
13. Lippman SM, Garewal HS, Meyskens FL Jr. Retinoids as potential chemopreventive agents in squamous cell carcinoma of the head and neck, Prev Med 1989; 18: 740–8.
14. Lippman SM, Hong WK. Differentiation agents: a future direction for the management of upper aerodigestive tract squamous cell carcinoma. In: Snow G, Clark JR, eds. Multimodality therapy for head and neck cancer. New York: Georg Thieme Verlag (in press).
15. Kraemer KH, DiGiovanna JJ, Moshell AN, Tarone RE, Peck GL. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633–7.
16. Lippman SM, Meyskens FL Jr. Treatment of advanced squamous cell carcinoma of the skin with isotretinoin. Ann Intern Med 1987; 107: 499–501.
17. Lippman SM, Kessler JF, Al-Sarraf M, et al. Treatment of advanced squamous cell carcinoma of the head and neck with isotretinoin: a phase II randomized trial. Invest New Drugs 1988; 6: 51–6.
18. Shklar G, Marefat P, Kornhauser A, Trickler DP, Wallace KD. Retinoid inhibition of lingual carcinogenesis. Oral Surg Oral Med Oral Pathol 1980; 49: 325–32.
19. Burge-Bottenbley A, Shklar G. Retardation of experimental oral cancer development by retinyl acetate. Nutr Cancer 1983; 5: 121–9.
20. Hennekens CH. Vitamin A analogues in cancer chemoprevention. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Important advances in oncology 1986. Philadelphia: J.B. Lippincott, 1986:23–35.
21. Bertram JS, Kolonel LN, Meyskens FL Jr. Rationale and strategies for chemoprevention of cancer in humans. Cancer Res 1987; 47: 3012–31.
22. Meyskens FL Jr. Thinking about cancer causality and chemoprevention. J Natl Cancer Inst 1988; 80: 1278–81.
23. Hong WK, Doos WG. Chemoprevention of head and neck cancer: potential use of retinoids. Otolaryngol Clin North Am 1985; 18: 543–9.
24. Evans RM. The steroid and thyroid hormone receptor superfamily. Science 1988; 240: 889–95.
25. Hong WK, Endicott J, Itri LM, et al. 13-cis-Retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501–5.
26. Beahrs OH, Myers MH, eds. Manual for staging of cancer. 2nd ed. Philadelphia: J.B. Lippincott, 1983:25–42.
27. Warren S, Gates O. Multiple primary malignant tumors: survey of literature and statistical study. Am J Cancer 1932; 16: 1358–414.
28. Snedecor GW, Cochran WG. Statistical methods. 6th ed. Ames: Iowa State University Press, 1967.
29. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–81.
30. Gehan EA. A generalized Wilcoxon test for comparing arbitrarily singly-censored samples. Biometrika 1965; 52: 203–23.
31. Breslow N. A generalized Kruskal-Wallis test for comparing K samples subject to unequal patterns of censorship. Biometrika 1970; 57: 579–94.
32. Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972; 34: 187–220.
33. Kalbfleisch JD, Prentice RL. The Statistical analysis of failure time data. New York: John Wiley, 1980.
34. Cooper JS, Pajak TF, Rubin P, et al. Second malignancies in patients who have head and neck cancer: incidence, effect on survival and implications based on the RTOG experience. Int J Radiat Oncol Biol Phys 1989; 17: 449–56.
35. McDonald S, Haie C, Rubin P, Nelson D, Divers LD. Second malignant tumors in patients with laryngeal carcinoma: diagnosis, treatment, and prevention. Int J Radiat Oncol Biol Phys 1989; 17: 457–65.
36. Licciardello JT, Spitz MR, Hong WK. Multiple primary cancer in patients with cancer of the head and neck: second cancer of the head and neck, esophagus, and lung. Int J Radial Oncol Biol Phys 1989; 17: 467–76.
37. Winn DM, Blot WJ. Second cancer following cancers of the buccal cavity and pharynx in Connecticut, 1935–1982. In: National Cancer Institute monograph 68. Washington, D.C.: Government Printing Office, 1985:25–48. (NIH publication no. 85–2714.)
38. Moore C. Cigarette smoking and cancer of the mouth, pharynx, and larynx: a continuing study. JAMA 1971; 218: 553–8.
39. Silverman S Jr, Gorsky M, Greenspan D. Tobacco usage in patients with head and neck carcinomas: a follow-up study on habit changes and second primary oral/oropharyngeal cancers. J Am Dent Assoc 1983; 106: 33–5.
40. Wynder EL, Dodo H, Bloch DA, Gantt RC, Moore OS. Epidemiologic investigation of multiple primary cancer of the upper alimentary and respiratory tracts. I. A retrospective study. Cancer 1969; 24: 730–9.
41. Hellquist H, Lundgren J, Olofsson J. Hyperplasia, keratosis, dysplasia and carcinoma in situ of the vocal cords — a follow-up study. Clin Otolaryngol 1982; 7: 11–27.
42. Gillis TM, Incze J, Strong MS, Vaughan CW, Simpson GT. Natural history and management of keratosis, alypia, carcinoma-in situ, and microinvasive cancer of the larynx. Am J Surg 1983; 146: 512–6.
43. Castigliano SG. Influence of continued smoking on the incidence of second primary cancers involving mouth, pharynx, and larynx. J Am Dent Assoc 1968; 77: 580–5.
44. Silverman S Jr, Gorsky M, Lozada F. Oral leukoplakia and malignant transformation: a follow-up study of 257 patients. Cancer 1984; 53: 563–8.
45. Lippman SM, Toth BB, Batsakis JG, et al. Low-dose 13-cis-retinoic acid (13cRA) maintains remission in oral premalignancy: more effective than β-carotene in randomized trial. Proc Am Soc Clin Oncol 1990; 9: 59. abstract.
46. Boone CW, Kelloff GJ, Malone WE. Identification of candidate cancer chemopreventive agents and their evaluation in animal models and human clinical trials: a review. Cancer Res 1990; 50: 2–9.
47. Trickler D, Shklar G. Prevention by vitamin E of experimental oral carcinogenesis. J Natl Cancer Inst 1987; 78: 165–9.
48. Suda D, Schwartz J, Shklar G. Inhibition of experimental oral carcinogenesis by topical beta carotene. Carcinogenesis 1986; 7: 711–5.
49. Stich HF, Rosin MP, Hornby AP, Mathew B, Sankaranarayanan R, Nair MK. Remission of oral leukoplakias and micronuclei in tobacco/betel quid chewers treated with beta-carotene and with beta-carotene plus vitamin A. Int J Cancer 1988; 42: 195–9.
50. Lippman SM, Lee JS, Lotan R, Hittelman W. Wargovich MJ, Hong WK. Biomarkers as intermediate end points in chemoprevention trials. J Natl Cancer Inst 1990; 82: 555–60.